Výsledky vyhledávání

P533 Adalimumab 80mg every other week in inflammatory bowel disease: Treatment intensification outcomes in real life clinical practice

Autor: Y. Gonzalez Lama, I Omella Usieto, V Matallana Royo, P Bella del Castillo, I. El Hajra Martinez, M I Vera Mendoza, E. Santos Perez, R De Lucas Téllez de Meneses, B Menchen Viso, B. Ruiz Antoran, M I Calvo Moya, M González Rodriguez, I Gonzalez Partida

Publikováno v: Journal of Crohn's and Colitis. 15:S507-S509

Background Adalimumab (ADA) intensification is recommended for inadequate or loss of response in inflammatory bowel disease (IBD) patients. A new presentation of ADA 80mg administered every other week (eow) has been approved as an alternative to ADA

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::af1ff9e265f5de7c11bb9147e3078299
https://doi.org/10.1093/ecco-jcc/jjab076.655

Zobrazit plný text záznamu

P545 Deep remission assessed by endoscopy, magnetic resonance or intestinal ultrasound, in refractory Crohn’s disease patients in clinical remission with ustekinumab: a real-life single-centre experience

Autor: P Bella del Castillo, Y. Gonzalez Lama, M I Vera Mendoza, R De Lucas Téllez de Meneses, V Matallana Royo, B Menchen Viso, I Gonzalez Partida, I Omella Usieto, M I Calvo Moya, M González Rodriguez

Publikováno v: Journal of Crohn's and Colitis. 14:S464-S465

Background Current therapeutic goals in Crohn’s disease (CD) include not only the mere absence of symptoms but also the objective resolution of macroscopic lesions, so-called deep remission (DR), which has been related to better outcomes. DR is usu

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::d4062b696f076332b07b5681da52c574
https://doi.org/10.1093/ecco-jcc/jjz203.673

Zobrazit plný text záznamu

P503 Changes in clinical use of vedolizumab are driven by lower drug costs and are associated with better outcomes: a real-life single-centre Spanish experience

Autor: I Gonzalez-Partida, M.I. Vera, I Omella, Y. Gonzalez Lama, Matallana, Mario Calvo

Publikováno v: Journal of Crohn's and Colitis. 14:S437-S438

Background Vedolizumab (VDZ) has shown efficacy in the treatment of inflammatory bowel disease (IBD). Available data show better outcomes in naïve patients than in AntiTNFa experienced patients, and current ECCO guidelines support first-line use of

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::36a8947ce0938a21064deb0bca505e90
https://doi.org/10.1093/ecco-jcc/jjz203.632

Zobrazit plný text záznamu

P378 Mucosal healing is achieved in most of the inflammatory bowel disease patients in clinical remission with vedolizumab: a real-life single-centre experience

Autor: V Matallana Royo, M González Rodriguez, Y. Gonzalez Lama, M Manso Manrique, I Omella Usieto, M I Vera Mendoza, I Gonzalez Partida, M I Calvo Moya, B Menchen Viso, R De Lucas Téllez de Meneses, P Bella del Castillo

Publikováno v: Journal of Crohn's and Colitis. 14:S355-S355

Background Current therapeutic goals in inflammatory bowel disease (IBD) include not only the mere absence of symptoms but also the resolution of endoscopic lesions, so-called mucosal healing (MH), which has been related to better outcomes. Data rega

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::b0ba48f9e961cd3d6e45036b14c5717e
https://doi.org/10.1093/ecco-jcc/jjz203.507

Zobrazit plný text záznamu

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Akademický článek

Treatment With Adalimumab 80 mg Every Other Week in Inflammatory Bowel Disease: Results of Treatment Intensification in Clinical Practice.

Autor: Calvo Moya M; Department of Gastroenterology and Hepatology, Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain., González Lama Y; Department of Gastroenterology and Hepatology, Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain., Ruíz Antorán B; Clinical Pharmacology Department, Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain., Omella Usieto I; Department of Gastroenterology and Hepatology, Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain., El Hajra Martinez I; Department of Gastroenterology and Hepatology, Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain., Santos Pérez E; Clinical Pharmacology Department, Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain., Menchén Viso B; Hospital Pharmacy Service, Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain., Matallana Royo V; Department of Gastroenterology and Hepatology, Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain., González Partida I; Department of Gastroenterology and Hepatology, Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain., de Lucas Tellez de Meneses R; Department of Gastroenterology and Hepatology, Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain., Bella Castillo P; Department of Gastroenterology and Hepatology, Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain., González Rodriguez M; Department of Gastroenterology and Hepatology, Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain., Vera Mendoza MI; Department of Gastroenterology and Hepatology, Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain.

Publikováno v: Crohn's & colitis 360 [Crohns Colitis 360] 2023 Jan 10; Vol. 5 (1), pp. otac051. Date of Electronic Publication: 2023 Jan 10 (Print Publication: 2023).

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání